Malaria control & elimination possible for India, challenges remain: Experts

Last Updated on April 25, 2023 by

<br>The country has made tremendous progress in its malaria elimination journey — observing a reduction of nearly 66 per cent in its official malaria burden between 2018 and 2022.

In 2021, India accounted for 79 per cent of all malaria cases of the Southeast Asia region, according to the World Malaria Report 2022, released by the World Health Organization (WHO). India also accounted for about 83 per cent of all malaria deaths in the region.

However, among the high burden and high impact countries in the SE Asia region, India showed a decline in deaths.

“Considering the huge success of Covid-19 control, India can do it — control and elimination of Malaria is absolutely possible for India, with political will and societal support,” Dr Nilima Kshirsagar, former National Chair and Emeritus Scientist ICMR, told IANS.

“While India’s progress deserves applause and acknowledgement, the road to elimination is still steep, and one ridden with critical challenges — India still accounts for the majority of the malaria burden of WHO’s Southeast Asia region,” added Pratik Kumar, Country Director, Malaria No More India — a nonprofit working in the country since 2016 to support India’s ambition of achieving malaria elimination by 2030.

Disruptions due to Covid, potential effects of climate change, humanitarian crisis, health system shortfall, limited donor funding are some of the challenges in combating malaria, Dr Nilima said.

These are further compounded by decline in effectiveness of our primary malaria fighting tool that is, insecticide treated nets and antimalarial drug regimen, she noted.

Malaria is a potentially life-threatening disease caused by parasites (plasmodium vivax, plasmodium falciparum, plasmodium malariae and plasmodium ovale) that are transmitted through the bite of infected female Anopheles mosquitoes.

In 2015, Prime Minister Narendra Modi, along with other 17 regional leaders committed India to eliminating malaria in Asia by 2030.

To receive the official certification of elimination by the WHO, India must achieve zero transmission of malaria cases by 2027 and sustain such transmission for the subsequent three years till 2030.

“India witnessed 85.1 per cent decline in malaria cases and 83.36 per cent decline in deaths during 2015-2022,” Union Health Minister Mansukh Mandaviya, said at the Asia-Pacific Leaders’ Conclave on Malaria Elimination on Monday.

Compared to 2019, India was the only high-burden, high-impact country in the SE Asia region to report a decline in malaria cases in 2020, he added.

“While elimination is a difficult goal under any circumstance, changing our strategic approach from control to elimination and addressing certain key gaps and challenges — such as absence of private sector in the fight, hidden malaria burden, lack of intersectoral action, exclusion of private health providers (local/traditional healers), and lax behaviour change communication — can help India achieve our ambition of eliminating the disease by 2030, in line with the Prime Minister’s vision,” Kumar told IANS.

To tackle malaria menace, several next generation antimalarial treatments are being developed. Some existing drugs are being repurposed, recombined and progressed for chemoprevention.

One of the important developments has been the Malaria vaccine. These target various stages of parasite cycle, pre-erythrocytic cycle stage, blood stage, sexual stage, malaria in pregnancy.

RTS,S/ASOI is an approved vaccine. Recently another vaccine R21/Matrix, manufactured by Serum Institute of India has been approved in Ghana and Nigeria for P.falciparum. For P. vivax there are three vaccines in development.

“To help India reach zero malaria by 2027, we need drugs that do not spend much time in the drug discovery pipeline. Drug repurposing is one such way for faster development of drugs,” Dr Shailja Singh, Special Centre for Molecular Medicine, Jawaharlal Nehru University, whose recent research was aimed at blocking the transmission of fatal malaria parasites, told IANS.

Her team identified Rocaglamide (Roc-A), a known inhibitor of Prohibitins and anti-cancerous agent as a potent antimalarial. They also reported the repurposing of the anti-hepatitis C virus drug alisporivir, a non-immunosuppressive analog of cyclosporin A, against artemisinin-resistant strains of P. falciparum.

Alisporivir exhibited potent antiparasitic effect against P. falciparum parasite, both in in vitro culture and in an in vivo mice model.

“Altogether, with the repurposing of alisporivir against malaria, our results support the hypothesis that targeting resistance mechanisms is a viable approach toward dealing with drug-resistant parasites,” Dr Shailja said.

(Rachel V Thomas can be contacted at [email protected])


Disclaimer: Medical Science is an ever evolving field. We strive to keep this page updated. In case you notice any discrepancy in the content, please inform us at [email protected]. You can futher read our Correction Policy here. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website or it's social media channels. Read our Full Disclaimer Here for further information.